- Condition: Branch Retinal Vein Occlusion
Interventions: Drug: Ranibizumab; Procedure: Laser
Sponsors: Novartis; Novartis Pharmaceuticals
Not yet recruiting - verified May 2012 - Condition: Age Related Macular Degeneration
Intervention:
Sponsors: Lawson Health Research Institute; Lawson Health Research Institute; The Physicians' Services Incorporated Foundation; Alternate Funding Plans for Academic Health Sciences Centres
Recruiting - verified April 2012 - Conditions: Macular Edema; Central Retinal Vein Occlusion
Intervention: Drug: Ranibizumab 0.5 mg/0.05 ml, intravitreal injection
Sponsors: Novartis; Novartis Pharmaceuticals
Not yet recruiting - verified March 2012 - Conditions: Blepharospasm; Hemifacial Spasm
Interventions: Drug: Zinc Supplement; Drug: Sugar pill
Sponsors: St. Joseph's Healthcare Hamilton; St. Joseph's Healthcare Hamilton
Not yet recruiting - verified March 2012 - Condition: RP (Retinitis Pigmentosa)
Intervention: Drug: QLT091001
Sponsors: QLT Inc.; QLT Inc.
Recruiting - verified March 2012 - Condition: Glaucoma
Intervention: Drug: Aqueous Suppressant Eye Drops
Sponsors: Credit Valley EyeCare; Credit Valley EyeCare; Canadian Glaucoma Clinical Research Council
Recruiting - verified February 2012 - Conditions: Glaucoma, Open-Angle; Ocular Hypertension
Interventions: Drug: travoprost 0.004% then bimatoprost 0.01%; Drug: travoprost 0.004% then travoprost 0.004%/timolol 0.5% combination
Sponsors: Allergan; Allergan
Recruiting - verified March 2012 - Condition: Optic Neuritis
Interventions: Drug: corticosteroids; Drug: corticosteroids
Sponsors: London Health Sciences Centre; London Health Sciences Centre; The Physicians' Services Incorporated Foundation
Not yet recruiting - verified January 2012 - Condition: Branch Retinal Vein Occlusion
Interventions: Drug: VEGF Trap-Eye; Device: Laser Treatment
Sponsors: Regeneron Pharmaceuticals; Regeneron Pharmaceuticals
Not yet recruiting - verified January 2012 - Condition: Epiretinal Membrane
Interventions: Procedure: Pars plana vitrectomy and epiretinal membrane peel; Procedure: ILM peel assisted by ICG; Procedure: CE-IOL
Sponsors: Sunnybrook Health Sciences Centre; Sunnybrook Health Sciences Centre
Recruiting - verified February 2012 - Conditions: LCA (Leber Congenital Amaurosis); RP (Retinitis Pigmentosa)
Intervention: Drug: QLT091001
Sponsors: QLT Inc.; QLT Inc.
Recruiting - verified April 2012 - Condition: Blindness
Intervention: Device: BrainPort Vision Device
Sponsors: Wicab; Wicab
Recruiting - verified December 2011 - Condition: Age Related Macular Degeneration
Interventions: Drug: Ranibizumab; Drug: Ranibizumab
Sponsors: University Health Network, Toronto; University Health Network, Toronto
Not yet recruiting - verified September 2011 - Condition: Eye Injuries
Intervention: Behavioral: Public Health strategies
Sponsors: Lawson Health Research Institute; Lawson Health Research Institute; Canadian National Institute for the Blind
Recruiting - verified December 2011 - Conditions: Parkinson's Disease; Insomnia
Interventions: Device: Light box (Litebook company); Behavioral: CBT and sleep hygiene; Drug: Doxepin and Zopiclone; Device: Light box ( Litebook company)
Sponsors: McGill University Health Center; McGill University Health Center
Recruiting - verified December 2011 - Condition: Age Related Macular Degeneration
Intervention: Drug: Ranibizumab
Sponsors: McMaster University; McMaster University; Canadian National Institute for the Blind
Not yet recruiting - verified May 2011 - Conditions: Ocular Hypertension; Primary Glaucoma
Interventions: Drug: Latanoprost, bimatoprost, travoprost; Drug: travoprost, latanoprost and bimatoprost
Sponsors: Centre Hospitalier Universitaire de Sherbrooke; Centre Hospitalier Universitaire de Sherbrooke
Recruiting - verified December 2010 - Conditions: Basal Cell Carcinoma; Gorlin Syndrome; Nevoid Basal Cell Carcinoma Syndrome
Interventions: Drug: LDE225; Drug: Placebo
Sponsors: Novartis; Novartis Pharmaceuticals
Recruiting - verified April 2012 - Condition: Cat Allergy
Intervention: Biological: Cat-PAD
Sponsors: Circassia Limited; Circassia Limited; Adiga Life Sciences
Recruiting - verified October 2011 - Condition: Cat Allergy
Intervention: Biological: Cat-PAD
Sponsors: Circassia Limited; Circassia Limited; Adiga Life Sciences
Recruiting - verified November 2011 - Condition: Retinal Detachment
Interventions: Drug: Dexamethasone Sodium Phosphate Injection; Drug: Saline Injection
Sponsors: University of Toronto; University of Toronto
Not yet recruiting - verified January 2011 - Conditions: Wet Age Related Macular Degeneration; Diabetic Macular Edema; Retinal Vein Occlusion
Intervention: Other: Ranibizumab
Sponsors: Novartis; Novartis Pharmaceuticals
Recruiting - verified January 2012 - Condition: Intracranial Aneurysm
Interventions: Procedure: flow diversion; Other: conservative management; Procedure: endovascular coiling; Procedure: balloon parent vessel occlusion; Procedure: surgical clipping
Sponsors: Centre hospitalier de l'Université de Montréal (CHUM); Centre hospitalier de l'Université de Montréal (CHUM); Centre de Recherche du Centre Hospitalier de l'Université de Montréal
Recruiting - verified December 2011 - Condition: Dry Eye Syndromes
Interventions: Drug: Formulation 1: Eye Drops New Platform (EDNP) - 1; Drug: Formulation 2: EDNP - 2; Drug: carboxymethylcellulose sodium based artificial tear
Sponsors: Allergan; Allergan
Recruiting - verified May 2012 - Condition: Macular Edema Following Cataract Surgery
Interventions: Drug: Trientine Hydrochloride; Other: For Arm B there is no therapeutic intervention other than standard of care, which is cataract surgery.
Sponsors: University of British Columbia; University of British Columbia
Not yet recruiting - verified April 2012 - Condition: Graves Ophthalmopathy
Interventions: Drug: Botulinum Toxin Type A; Drug: Saline injection
Sponsors: University of Toronto; University of Toronto; Allergan
Not yet recruiting - verified December 2010 - Conditions: Glaucoma; Glaucoma, Open Angle
Intervention: Device: SOLX Gold Shunt
Sponsors: SOLX, Inc.; SOLX, Inc.
Recruiting - verified April 2012 - Condition: Fasciitis, Plantar
Interventions: Other: Karaoke Exercise; Other: Balance walking exercise; Other: Forefoot extension exercise; Other: Standing one-legged balance exercise:; Other: Ankle inversion/eversion exercise; Other: Gastrocnemius and soleus stretching; Other: Tissue-specific plantar fascia self massage; Drug: Dexamethasone
Sponsors: University of British Columbia; University of British Columbia
Recruiting - verified February 2012 - Condition: Glaucoma
Interventions: Device: portable CCTV; Device: Telescopes, telemicroscopes and microscopes; Device: Absorptive filters
Sponsors: Lawson Health Research Institute; Lawson Health Research Institute; Pfizer
Recruiting - verified August 2011 - Condition: Noninfectious Uveitis
Intervention: Drug: LX211
Sponsors: Lux Biosciences, Inc.; Lux Biosciences, Inc.
Recruiting - verified May 2011 - Condition: Glaucoma
Intervention: Drug: Bevacizumab
Sponsors: Capital District Health Authority, Canada; Capital District Health Authority, Canada
Recruiting - verified June 2011 - Condition: Diabetic Retinopathy
Interventions: Drug: Trientine Hydrochloride; Drug: Oral placebo capsules
Sponsors: University of British Columbia; University of British Columbia
Recruiting - verified June 2011 - Condition: Cardiac Iron Overload
Intervention: Drug: Deferasirox and Deferoxamine
Sponsors: Novartis; Novartis Pharmaceuticals
Recruiting - verified May 2012 - Conditions: Glaucoma; Optic Neuropathy; Fibrosis
Interventions: Drug: Bevacizumab; Drug: Control
Sponsors: Sunnybrook Health Sciences Centre; Sunnybrook Health Sciences Centre; Glaucoma Research Society of Canada
Recruiting - verified July 2011 - Condition: Diabetic Macular Edema
Interventions: Drug: ranibizumab + laser photocoagulation; Drug: ranibizumab; Procedure: laser photocoagulation
Sponsors: Novartis; Novartis
Recruiting - verified April 2012 - Condition: Non Squamous Lung Cancer
Interventions: Drug: treatment; Drug: treatment
Sponsors: Pfizer; Pfizer
Recruiting - verified April 2012 - Condition: Uveitis
Interventions: Drug: adalimumab; Drug: prednisone; Drug: adalimumab placebo; Drug: prednisone
Sponsors: Abbott; Abbott
Recruiting - verified February 2012 - Condition: Uveitis
Interventions: Drug: adalimumab; Drug: prednisone; Drug: prednisone; Drug: adalimumab placebo
Sponsors: Abbott; Abbott
Recruiting - verified February 2012 - Conditions: Glaucoma; Inflammatory Response
Intervention: Procedure: Selective Laser trabeculoplasty
Sponsors: Laval University; Laval University; Canadian Glaucoma Clinical Research Council; Pfizer
Recruiting - verified December 2009 - Conditions: LCA (Leber Congenital Amaurosis); RP (Retinitis Pigmentosa)
Intervention: Drug: QLT091001
Sponsors: QLT Inc.; QLT Inc.
Recruiting - verified April 2012 - Condition: Age-related Macular Degeneration
Intervention: Dietary Supplement: Ocean Nutrition MEG3 4020EE product
Sponsors: University of Alberta; Yves Sauve; Canadian Institutes of Health Research (CIHR)
Not yet recruiting - verified November 2011 - Condition: Idiopathic Intracranial Hypertension
Interventions: Drug: Acetazolamide; Drug: Placebo; Behavioral: Formal weight loss counselling program
Sponsors: St. Luke's-Roosevelt Hospital Center; St. Luke's-Roosevelt Hospital Center; National Eye Institute (NEI); University of Rochester; University of Iowa; University of California, Davis
Recruiting - verified March 2012 - Condition: AMD
Interventions: Behavioral: eccentric viewing (EV) training; Device: Closed circuit television (CCTV)
Sponsors: Lawson Health Research Institute; Lawson Health Research Institute
Recruiting - verified June 2011 - Conditions: Cancer; Cataract; Low Bone Mineral Density; Osteopenia; Osteoporosis; Prostate Cancer
Interventions: Biological: Denosumab; Biological: Placebo
Sponsors: Amgen; Amgen
Recruiting - verified March 2012 - Condition: Open Angle Glaucoma
Interventions: Procedure: Trabectome +/- Cataract Surgery; Procedure: Trabeculectomy with Mitomycin C +/- Cataract Surgery
Sponsors: University of Alberta; University of Alberta
Recruiting - verified April 2012 - Condition: Glaucoma
Interventions: Drug: ranibizumab; Procedure: standard care
Sponsors: Maisonneuve-Rosemont Hospital; Maisonneuve-Rosemont Hospital; Novartis
Recruiting - verified April 2012 - Conditions: Purpura, Thrombocytopenic, Idiopathic; Immune Thrombocytopenic Purpura
Interventions: Drug: eltrombopag; Drug: Placebo
Sponsors: GlaxoSmithKline; GlaxoSmithKline
Recruiting - verified March 2012 - Condition: Anterior Ischemic Optic Neuropathy
Intervention: Drug: Diagnostic procedures
Sponsors: Bayer; Bayer
Recruiting - verified May 2012 - Conditions: Diabetic Retinopathy; Diabetic Macular Edema
Interventions: Procedure: islet cell transplant; Other: Medical therapy
Sponsors: University of British Columbia; University of British Columbia
Recruiting - verified November 2011 - Condition: Non-arteritic Anterior Ischemic Optic Neuropathy
Intervention: Drug: Intra-vitreal injection of bevacizumab (1.25mg/0.05ml)
Sponsors: Mount Sinai Hospital, Canada; Mount Sinai Hospital, Canada
Recruiting - verified February 2012 - Condition: Myasthenia Gravis
Interventions: Drug: Methotrexate; Other: Placebo
Sponsors: University of Kansas; University of Kansas; Food and Drug Administration (FDA)
Recruiting - verified March 2012 - Conditions: Nearsightedness; Farsightedness; Astigmatism
Intervention:
Sponsors: Ottawa Hospital Research Institute; Ottawa Hospital Research Institute
Recruiting - verified October 2011 - Condition: Retinoblastoma
Interventions: Genetic: DNA ploidy analysis; Genetic: DNA stability analysis; Genetic: Southern blotting; Genetic: genetic linkage analysis; Genetic: loss of heterozygosity analysis; Genetic: mutation analysis; Genetic: polymorphism analysis; Genetic: reverse transcriptase-polymerase chain reaction; Other: environmental carcinogenesis study; Other: questionnaire administration; Other: study of socioeconomic and demographic variables; Procedure: evaluation of cancer risk factors; Procedure: mutation carrier screening
Sponsors: National Cancer Institute (NCI); Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified May 2012 - Conditions: Cataract; Phacoemulsification; Mydriasis; Pseudoexfoliation Syndrome
Intervention: Procedure: Intracameral injection of mydriatic agent
Sponsors: Capital District Health Authority, Canada; Capital District Health Authority, Canada
Recruiting - verified May 2008 - Condition: Retinoblastoma
Interventions: Biological: filgrastim; Drug: carboplatin; Drug: cisplatin; Drug: cyclophosphamide; Drug: etoposide; Drug: thiotepa; Drug: vincristine sulfate; Procedure: autologous bone marrow transplantation; Procedure: autologous hematopoietic stem cell transplantation; Procedure: peripheral blood stem cell transplantation; Radiation: radiation therapy
Sponsors: National Cancer Institute (NCI); Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified May 2012 - Condition: Progressive Supranuclear Palsy
Intervention:
Sponsors: University of Louisville; University of Louisville; National Institute on Aging (NIA)
Recruiting - verified December 2011 - Condition: Acquired Brain Injury (Including Stroke)
Interventions: Behavioral: Facial Affect Recognition Training; Other: Stories of Emotional Inference
Sponsors: University at Buffalo; University at Buffalo; U.S. Department of Education; Massey University; Carolinas Healthcare System; Brock University
Recruiting - verified April 2012 - Condition: Retinoblastoma
Interventions: Biological: filgrastim; Drug: carboplatin; Drug: cyclosporine; Drug: etoposide; Drug: vincristine sulfate; Procedure: cryosurgery; Procedure: laser therapy; Procedure: neoadjuvant therapy
Sponsors: National Cancer Institute (NCI); The Hospital for Sick Children
Recruiting - verified April 2009
 |
Join Clinical Trials for Eye Diseases in Canada |
